Allison Bratzel
Stock Analyst at Piper Sandler
(4.71)
# 155
Out of 5,130 analysts
48
Total ratings
68.42%
Success rate
23.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Overweight | $28 → $30 | $7.41 | +304.86% | 1 | Nov 11, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $820 → $930 | $788.49 | +17.95% | 15 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $26 → $35 | $34.58 | +1.21% | 3 | Nov 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $70 → $77 | $80.30 | -4.11% | 3 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $82 → $102 | $106.87 | -4.56% | 3 | Nov 4, 2025 | |
| IOBT IO Biotech | Maintains: Overweight | $10 → $3 | $0.56 | +433.43% | 1 | Oct 22, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $52 → $51 | $42.18 | +20.91% | 4 | Sep 24, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $114.40 | -2.10% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $8.03 | +173.97% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $29.31 | +12.59% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $22.51 | +410.88% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $6 | $1.52 | +294.74% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $8.81 | +195.12% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $40.84 | -43.68% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $21.98 | +0.09% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.17 | +241.88% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $5.29 | +278.07% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $4.37 | +357.67% | 1 | Oct 13, 2023 |
MeiraGTx Holdings
Nov 11, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $7.41
Upside: +304.86%
argenx SE
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $788.49
Upside: +17.95%
Travere Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $26 → $35
Current: $34.58
Upside: +1.21%
Ionis Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $70 → $77
Current: $80.30
Upside: -4.11%
Incyte
Nov 4, 2025
Maintains: Overweight
Price Target: $82 → $102
Current: $106.87
Upside: -4.56%
IO Biotech
Oct 22, 2025
Maintains: Overweight
Price Target: $10 → $3
Current: $0.56
Upside: +433.43%
Scholar Rock Holding
Sep 24, 2025
Maintains: Overweight
Price Target: $52 → $51
Current: $42.18
Upside: +20.91%
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $114.40
Upside: -2.10%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $8.03
Upside: +173.97%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $29.31
Upside: +12.59%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $22.51
Upside: +410.88%
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $1.52
Upside: +294.74%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $8.81
Upside: +195.12%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $40.84
Upside: -43.68%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $21.98
Upside: +0.09%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.17
Upside: +241.88%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $5.29
Upside: +278.07%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $4.37
Upside: +357.67%